Abstract | STUDY OBJECTIVE: DESIGN: Prospective, multicenter, randomized, parallel group, double-blind placebo-controlled 12-week trial. PATIENTS: INTERVENTIONS: MEASUREMENTS AND MAIN RESULTS: The number of painful joints and swollen joints, joint pain and joint swelling indices, left and right grip strength, investigator global assessment, and patient global assessment returned to baseline for the amiprilose group and showed statistically significant (P less than 0.05) differences from the placebo group within 4 to 6 weeks. The protocol criteria for overall therapeutic response were satisfied by 41% of the amiprilose patients, compared with 21% of the placebo group (P = 0.003). Approximately 0.5 tablet per day less analgesic medication was taken by the amiprilose group (P less than 0.05 at weeks 6 and 12). There were no statistically significant differences in morning stiffness, walking time, erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor between the groups. A similar number of adverse experiences were reported by the patients on amiprilose (67%) and on placebo (63%). One patient on amiprilose developed thrombocytopenia of unknown cause; no other reported adverse effects were serious. CONCLUSIONS:
|
Authors | W G Riskin, D B Gillings, J A Scarlett |
Journal | Annals of internal medicine
(Ann Intern Med)
Vol. 111
Issue 6
Pg. 455-65
(Sep 15 1989)
ISSN: 0003-4819 [Print] United States |
PMID | 2672925
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adjuvants, Immunologic
- Ribose
- Glucosamine
- amiprilose
|
Topics |
- Adjuvants, Immunologic
(adverse effects, therapeutic use)
- Arthritis, Rheumatoid
(blood, drug therapy, physiopathology)
- Double-Blind Method
- Drug Evaluation
- Female
- Glucosamine
(adverse effects, analogs & derivatives, therapeutic use)
- Humans
- Joints
(physiopathology)
- Male
- Middle Aged
- Multicenter Studies as Topic
- Random Allocation
- Ribose
(analogs & derivatives)
- Specific Gravity
- Thrombocytopenia
(chemically induced)
- Urine
(analysis)
- Vision Disorders
(chemically induced)
|